Treatment of Mitomycin-Associated Microangiopathic Hemolytic Anemia With Vincristine

Jean L. Grem, James A. Merritt, Paul P. Carbone

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A syndrome, including microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and renal insufficiency, has been recognized to occur as a complication of antineoplastic therapy with mitomycin. The clinical presentation can vary from a chronic course with mild anemia and slowly progressive renal dysfunction to a fulminant course with severe anemia, rapid deterioration of renal function, and death. The optimal treatment of the mitomycin-associated MAHA syndrome is unknown. Therapy with steroids, antiplatelet agents, and heparin sodium has failed to reverse the MAHA. Plasmapheresis has improved the MAHA in a few patients without reversing the renal failure. We treated two patients who had MAHA and renal dysfunction during chemotherapy that included mitomycin; the MAHA and hypertension both objectively improved after treatment that included vincristine sulfate.

Original languageEnglish (US)
Pages (from-to)566-568
Number of pages3
JournalArchives of Internal Medicine
Volume146
Issue number3
DOIs
StatePublished - Mar 1986

Fingerprint

Hemolytic Anemia
Mitomycin
Vincristine
Kidney
Renal Insufficiency
Anemia
Therapeutics
Plasmapheresis
Platelet Aggregation Inhibitors
Thrombocytopenia
Antineoplastic Agents
Heparin
Steroids
Hypertension
Drug Therapy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Treatment of Mitomycin-Associated Microangiopathic Hemolytic Anemia With Vincristine. / Grem, Jean L.; Merritt, James A.; Carbone, Paul P.

In: Archives of Internal Medicine, Vol. 146, No. 3, 03.1986, p. 566-568.

Research output: Contribution to journalArticle

Grem, Jean L. ; Merritt, James A. ; Carbone, Paul P. / Treatment of Mitomycin-Associated Microangiopathic Hemolytic Anemia With Vincristine. In: Archives of Internal Medicine. 1986 ; Vol. 146, No. 3. pp. 566-568.
@article{7466be5690a34f14848f8054a61b847d,
title = "Treatment of Mitomycin-Associated Microangiopathic Hemolytic Anemia With Vincristine",
abstract = "A syndrome, including microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and renal insufficiency, has been recognized to occur as a complication of antineoplastic therapy with mitomycin. The clinical presentation can vary from a chronic course with mild anemia and slowly progressive renal dysfunction to a fulminant course with severe anemia, rapid deterioration of renal function, and death. The optimal treatment of the mitomycin-associated MAHA syndrome is unknown. Therapy with steroids, antiplatelet agents, and heparin sodium has failed to reverse the MAHA. Plasmapheresis has improved the MAHA in a few patients without reversing the renal failure. We treated two patients who had MAHA and renal dysfunction during chemotherapy that included mitomycin; the MAHA and hypertension both objectively improved after treatment that included vincristine sulfate.",
author = "Grem, {Jean L.} and Merritt, {James A.} and Carbone, {Paul P.}",
year = "1986",
month = "3",
doi = "10.1001/archinte.1986.00360150204025",
language = "English (US)",
volume = "146",
pages = "566--568",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Treatment of Mitomycin-Associated Microangiopathic Hemolytic Anemia With Vincristine

AU - Grem, Jean L.

AU - Merritt, James A.

AU - Carbone, Paul P.

PY - 1986/3

Y1 - 1986/3

N2 - A syndrome, including microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and renal insufficiency, has been recognized to occur as a complication of antineoplastic therapy with mitomycin. The clinical presentation can vary from a chronic course with mild anemia and slowly progressive renal dysfunction to a fulminant course with severe anemia, rapid deterioration of renal function, and death. The optimal treatment of the mitomycin-associated MAHA syndrome is unknown. Therapy with steroids, antiplatelet agents, and heparin sodium has failed to reverse the MAHA. Plasmapheresis has improved the MAHA in a few patients without reversing the renal failure. We treated two patients who had MAHA and renal dysfunction during chemotherapy that included mitomycin; the MAHA and hypertension both objectively improved after treatment that included vincristine sulfate.

AB - A syndrome, including microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and renal insufficiency, has been recognized to occur as a complication of antineoplastic therapy with mitomycin. The clinical presentation can vary from a chronic course with mild anemia and slowly progressive renal dysfunction to a fulminant course with severe anemia, rapid deterioration of renal function, and death. The optimal treatment of the mitomycin-associated MAHA syndrome is unknown. Therapy with steroids, antiplatelet agents, and heparin sodium has failed to reverse the MAHA. Plasmapheresis has improved the MAHA in a few patients without reversing the renal failure. We treated two patients who had MAHA and renal dysfunction during chemotherapy that included mitomycin; the MAHA and hypertension both objectively improved after treatment that included vincristine sulfate.

UR - http://www.scopus.com/inward/record.url?scp=0022534470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022534470&partnerID=8YFLogxK

U2 - 10.1001/archinte.1986.00360150204025

DO - 10.1001/archinte.1986.00360150204025

M3 - Article

C2 - 3954531

AN - SCOPUS:0022534470

VL - 146

SP - 566

EP - 568

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 3

ER -